<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04233060</url>
  </required_header>
  <id_info>
    <org_study_id>CS3005-101</org_study_id>
    <nct_id>NCT04233060</nct_id>
  </id_info>
  <brief_title>A Study of CS3005 in Advanced Solid Tumors</brief_title>
  <official_title>A Phase I, Multi-center, Open-label, Dose Escalation Study of CS3005 in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CStone Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CStone Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I, Multi-center, Open-label, Dose Escalation Study of CS3005 in Subjects with&#xD;
      Advanced Solid Tumors&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>From the day of first dose to 30 days (±7 days) after last dose of CS3005, up to 2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>CS3005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS3005</intervention_name>
    <description>CS3005 will be orally administrated twice daily (BID) until PD, unacceptable toxicity, withdrawal of informed consent, or until maximum treatment duration per protocol (2 years)</description>
    <arm_group_label>CS3005</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General&#xD;
&#xD;
          1. Be willing and able to provide written informed consent form for the trial.&#xD;
&#xD;
          2. Male or female between 18 to 75 years of age.&#xD;
&#xD;
          3. Ability to comply with requirements of the protocol, as assessed by the investigator.&#xD;
&#xD;
          4. Subjects who were histologically confirmed advanced solid tumor shall have progressed&#xD;
             disease and/or experienced intolerance from prior standard therapies, or for whom no&#xD;
             standard of care (SoC) therapies exist.&#xD;
&#xD;
          5. Subject must have at least one measurable lesion by CT or MRI; radiographic tumor&#xD;
             assessment should be performed within 28 days prior to the first dose of study&#xD;
             treatment.&#xD;
&#xD;
          6. ECOG performance status score of 0 or 1&#xD;
&#xD;
          7. Prior immunotherapy is allowed&#xD;
&#xD;
          8. Subjects who have previously received anti-tumor therapy will only be enrolled if the&#xD;
             toxicities from the previous treatment have returned to the baseline level or NCI&#xD;
             CTCAE v 5.0 grade ≤1.&#xD;
&#xD;
          9. Subject must have adequate organ function as indicated by the following laboratory&#xD;
             values, G-CSF or other relevant medical support within 14 days before the&#xD;
             administration of the investigational product&#xD;
&#xD;
         10. Subjects with active hepatitis B or active hepatitis C must receive antiviral&#xD;
             treatment and pass the HBV DNA titer test and HCV RNA test before being enrolled. The&#xD;
             subject should be willing to continue effective anti-viral treatment during the study.&#xD;
&#xD;
         11. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test&#xD;
             result. Either Female or male subjects must agree to use adequate contraceptive&#xD;
             measures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has disease that is suitable for local treatment administered with curative intent&#xD;
&#xD;
          2. Has a history of a second malignancy active within the previous 3 years except for&#xD;
             locally curable cancers that have been apparently cured.&#xD;
&#xD;
          3. Patients with any condition that impairs their ability to take oral medication.&#xD;
&#xD;
          4. Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.&#xD;
&#xD;
          5. Subjects with active, known, or suspected autoimmune disease in the past 3 years prior&#xD;
             to the start of treatment.&#xD;
&#xD;
          6. History of active tuberculosis, both pulmonary and extrapulmonary.&#xD;
&#xD;
          7. Clinically Significant history of cardiac disease within 6 months prior to 1st dosing,&#xD;
             myocardial infarction within the previous year, or current cardiac ventricular&#xD;
             arrhythmias requiring medication.&#xD;
&#xD;
          8. Subjects with ascites, pleural effusion, pericardial effusion which cannot be reversed&#xD;
             by appropriate interventions.&#xD;
&#xD;
          9. Subjects with any active infections requiring systemic therapy within 2 weeks prior to&#xD;
             the initiation of the study treatment.&#xD;
&#xD;
         10. Known history of positive test for human immunodeficiency virus (HIV) or known&#xD;
             acquired immunodeficiency syndrome.&#xD;
&#xD;
         11. History of organ transplant that requires the use of immunosuppressive treatment.&#xD;
&#xD;
         12. For post immunotherapy patients, with prior ≥ Grade 3, serious, or life-threatening&#xD;
             immune-mediated reactions following prior anti-PD-(L)1 or other immune-oncology&#xD;
             therapies.&#xD;
&#xD;
         13. Subjects who have received systemic anti-tumor treatments 21 days prior to the&#xD;
             initiation of the study treatment.&#xD;
&#xD;
         14. Subjects who have received treatment with approved anti-tumor Chinese herbal medicine&#xD;
             or Chinese prepared.&#xD;
&#xD;
         15. Subjects with a condition requiring systemic treatment with either corticosteroids or&#xD;
             other immunosuppressive medications.&#xD;
&#xD;
         16. Has received treatment with non-selective adenosine antagonist or A2a receptor&#xD;
             antagonist.&#xD;
&#xD;
         17. Concurrent administration of strong inhibitors or inducers of CYP3A4 and CYP1A2 is not&#xD;
             permitted&#xD;
&#xD;
        For more information regarding trial participation, please contact at&#xD;
        cstonera@cstonepharma.com&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fei Li, PhD</last_name>
    <role>Study Director</role>
    <affiliation>CStone Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wendie Yuan</last_name>
    <phone>8617621040459</phone>
    <phone_ext>8617621040459</phone_ext>
    <email>cstonera@cstonepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scientia Clinical Research Ltd</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Lemech</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

